The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
Company Details
- Employees
- 80
- Founded
- -
- Address
- 300 Morris St, Suite 320,united States
- Industry
- Biotechnology
- Website
- https://www.tunetx.com
- HQ
- Durham, North Carolina
Tune Therapeutics Questions
Tune Therapeutics's website is https://www.tunetx.com
Tune Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tunetx
Tune Therapeutics has
80 employees.
View email and phone details for 80
employees at Tune Therapeutics.
Tune Therapeutics's industry is
Biotechnology
Tune Therapeutics's top competitors are
Windward Bio,
Normunity,
Shape Therapeutics Inc.,
Umoja Biopharma,
Timberlyne Therapeutics,
Light Horse Therapeutics,
Ouro Medicines,
Sana Biotechnology, Inc.,
Kardigan,
Be Biopharma.
Tune Therapeutics's categories are Biotechnology
Tune Therapeutics's founding year is 2020
